FDA-approved Product
Therapy Areas
Sanofi is advancing the future of Type 1 Diabetes care by focusing on early detection, immune intervention, and preservation of beta cell function to delay disease progression
Educational Resources
Type 1 Diabetes
American Diabetes Association Standards of Care in T1D – 2026
Select updates from section 2 and 3 pertaining to T1D. For a comprehensive overview of all changes, refer to the 2026 Standards of Care
Adult Onset T1D
Common clinical considerations and/or procedural steps for the diagnosis and management of early-stage T1D adult patients
T1D Mechanism of Disease
Video highlighting the mechanism of beta cell loss caused by autoimmune T Cells
The Value of Beta-Cell Preservation
Overview of C-peptide testing in assessing beta cell function and the implications of beta cell preservation in managing T1D
Consensus Guidelines for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 T1D
Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes | Diabetes Care | American Diabetes Association
Sanofi does not review or control the content of non-Sanofi websites.
Engage with Sanofi Payer Medical
Explore Other Therapy Areas
Immunology and Inflammation Resources
Neurology Resources
Oncology Resources
Rare Blood Disorders Resources
Member Engagement and Population Health Resources
Rare Diseases
Chronic Graft-versus-Host Disease
